Sutro Biopharma Inc logo

Sutro Biopharma Inc

NAS:STRO (USA)  
$ 3.71 -0.05 (-1.33%) 10:08 PM EST
At Loss
P/B:
2.36
Market Cap:
$ 303.46M
Enterprise V:
$ 18.31M
Volume:
403.41K
Avg Vol (2M):
793.03K
Also Trade In:
Volume:
403.41K
At Loss
Avg Vol (2M):
793.03K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Sutro Biopharma Inc ( ) from 2018 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sutro Biopharma stock (STRO) PE ratio as of Jun 10 2024 is 0. More Details

Sutro Biopharma Inc (STRO) PE Ratio (TTM) Chart

To

Sutro Biopharma Inc (STRO) PE Ratio (TTM) Historical Data

Total 1251
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Sutro Biopharma PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-10 At Loss 2024-04-08 At Loss
2024-06-07 At Loss 2024-04-05 At Loss
2024-06-06 At Loss 2024-04-04 At Loss
2024-06-05 At Loss 2024-04-03 At Loss
2024-06-04 At Loss 2024-04-02 At Loss
2024-06-03 At Loss 2024-04-01 At Loss
2024-05-31 At Loss 2024-03-29 At Loss
2024-05-30 At Loss 2024-03-28 At Loss
2024-05-29 At Loss 2024-03-27 At Loss
2024-05-28 At Loss 2024-03-26 At Loss
2024-05-27 At Loss 2024-03-25 At Loss
2024-05-24 At Loss 2024-03-22 At Loss
2024-05-23 At Loss 2024-03-21 At Loss
2024-05-22 At Loss 2024-03-20 At Loss
2024-05-21 At Loss 2024-03-19 At Loss
2024-05-20 At Loss 2024-03-18 At Loss
2024-05-17 At Loss 2024-03-15 At Loss
2024-05-16 At Loss 2024-03-14 At Loss
2024-05-15 At Loss 2024-03-13 At Loss
2024-05-14 At Loss 2024-03-12 At Loss
2024-05-13 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss
2024-04-22 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss

Sutro Biopharma Inc (STRO) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.